Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Colorcon
AstraZeneca
Baxter
Merck

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Litigation Details for Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (D. Del. 2017)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (D. Del. 2017)

Docket   Start Trial Date Filed 2017-12-12
Court District Court, D. Delaware Date Terminated
Cause 28:2201 Declaratory Judgment Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties CEPHALON, INC.; EAGLE PHARMACEUTICALS, INC.; MYLAN LABORATORIES LIMITED; TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Patents 8,609,707; 8,791,270; 9,000,021; 9,034,908; 9,144,568; 9,265,831; 9,572,796; 9,572,797; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Attorneys Anna G. Phillips; Ben V. Picozzi; Daniel G. Brown; James Michael Lennon; John W. Shaw; Karen Elizabeth Keller; Kenneth G. Schuler; Marc N. Zubick; Michelle L. Ernst; Nathan Roger Hoeschen; Nicole W. Stafford; Shyamkrishna Palaiyanur
Firms Devlin Law Firm LLC; Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 expiration of U.S. Patent Nos. 8,791,270 (“the ’270 patent”); 8,609,707 (“the ’707 patent”); 9,265,831 (“…COUNT II – INFRINGEMENT OF U.S. PATENT NO. 8,609,707 UNDER 35 U.S.C. § 271(e)(2) … INFRINGEMENT OF U.S. PATENT NO. 8,609,707 204. Plaintiffs incorporate…’270 patent, the ’707 patent, the ’831 patent, the ’796 patent, the ’797 patent, the ’908 patent, the…’568 patent, the ’887 patent, the ’397 patent, the ’398 patent, the ’399 patent, the ’021 patent, and External link to document
0000-00-00 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,609,707 B2; US 8,791,270 …12 December 2017 1:17-cv-01790 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Baxter
Mallinckrodt
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.